Skip to main content
. 2020 Mar 17;2(1):1–10. doi: 10.1016/j.jaccao.2020.02.003

Figure 1.

Figure 1

Study Cohort

CTRCD, as defined by a decrease in LVEF of more than 10 % to <53% LVEF, was observed in 4 patients (black box). The remaining 32 patients did not experience CTRCD (white box). CTRCD = cancer therapeutics-related cardiac dysfunction; LVEF = left ventricular ejection fraction; NSCLC = non–small cell lung cancer.